The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer
- 3 Downloads
Vaginal atrophy is one of the most common side effects of using tamoxifen in women with breast cancer. Hormone therapy for vaginal atrophy is prohibited in these women. The present study was conducted to investigate the effect of vitamin D and E vaginal suppositories on vaginal atrophy in women with breast cancer receiving tamoxifen.
Women under breast cancer management receiving tamoxifen and showing symptoms of vaginal atrophy were randomized triple-blind to an 8-week trial on vaginal suppository vitamin E or vitamin D or placebo administered every night before bedtime. The genitourinary atrophy self-assessment tool was administered, and pH was measured in all three groups before the intervention and at the end of weeks 2, 4, and 8 of the intervention. The Vaginal Maturation Index (VMI) was also measured before the intervention and at the end of the eighth week. Data were analyzed with paired t tests, repeated measures analysis of variance, and chi-square test.
Thirty-two patients were randomized in each group. The results obtained showed an increase in the VMI by the end of the eighth week of the intervention in the groups receiving the vitamin D and E vaginal suppositories compared with the placebo group (P < 0.001). The vaginal pH also reduced in both groups compared with that in the placebo group (P < 0.001). The symptoms of self-reported genitourinary atrophy also improved in the two intervention groups compared with those in the placebo group by the end of the eighth week (P < 0.001).
These data support that vitamin D and E vaginal suppositories were beneficial in improving vaginal atrophy in women with breast cancer receiving tamoxifen. Given the prohibition on hormone therapy in these women, the suppositories can be used as an alternative therapy to improve these symptoms.
KeywordsBreast cancer Tamoxifen Atrophic vaginitis Vitamin D Vitamin E Vaginal suppository
Compliance with ethical standards
The research project was approved by the ethics committee of Shiraz University of Medical Sciences (IR.SUMS.REC 94-01-08-11247) and registered at the Iranian Registry of Clinical Trials (IRCT2016100229683N2).
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Berek JS (2012) Berek and Novak’s gynecology. Lippincott Williams and Wilkins, PhiladelphiaGoogle Scholar
- 2.Enayatrad M, Amoori N, Salehiniya H (2015) Epidemiology and trends in breast cancer mortality in Iran. Iran J Public Health 44(3):430–431Google Scholar
- 3.Del Mastro L, Boni L, Michelotti A et al (2011) Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306(3):269–276. https://doi.org/10.1001/jama.2011.991 Google Scholar
- 5.Kim NN, Stankovic M, Armagan A, Cushman TT, Goldstein I, Traish AM (2006) Effects of tamoxifen on vaginal blood flow and epithelial morphology in the rat. BMC Womens Health 6:14Google Scholar
- 11.Bergendal A, Kieler H, Sundström A, Hirschberg AL, Kocoska-Maras L (2016) Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause 23(6):593–599. https://doi.org/10.1097/GME.0000000000000611 Google Scholar
- 14.Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, Kaunitz AM, Krychman ML, Parish SJ, Partridge AH, Pinkerton JAV, Rowen TS, Shapiro M, Simon JA, Goldfarb SB, Kingsberg SA (2018) Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause 25(6):596–608. https://doi.org/10.1097/GME.0000000000001121 Google Scholar
- 15.American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice, Farrell R (2016) ACOG Committee Opinion No. 659 Summary: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 127(3):618–619. https://doi.org/10.1097/AOG.0000000000001349 Google Scholar
- 16.Costantino D, Guaraldi C (2008) Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial. Eur Rev Med Pharmacol Sci 12(6):411–416Google Scholar
- 20.Derzko C, Elliott S, Lam W (2007) Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 14(Suppl 1):S20–S40Google Scholar
- 21.Juraskova I, Jarvis S, Mok K, Peate M, Meiser B, Cheah BC, Mireskandari S, Friedlander M (2013) The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. J Sex Med 10(10):2549–2558. https://doi.org/10.1111/jsm.12156 Google Scholar
- 23.Yildirim B, Kaleli B, Düzcan E, Topuz O (2004) The effects of postmenopausal vitamin D treatment on vaginal atrophy. Maturitas 49(4):334–337Google Scholar
- 24.Rad P, Tadayon M, Abbaspour M, Latifi SM, Rashidi I, Delaviz H The effect of vitamin D on vaginal atrophy in postmenopausal women. Iran J Nurs Midwifery Res 20(2):211–215Google Scholar
- 25.Lee A, Lee MR, Lee HH et al (2017) Vitamin D proliferates vaginal epithelium through RhoA expression in postmenopausal atrophic vagina tissue. Mol Cell 40(9):677–684Google Scholar
- 26.Ziagham S, Abbaspoor Z, Safyari S, Rad P (2013) Effect of vitamin E vaginal suppository on atrophic vaginitis among postmenopausal women. Jundishapur J Chronic Dis Care 2(4):12–19Google Scholar
- 27.Abban G, Yildirim NB, Jetten AM (2008) Regulation of the vitamin D receptor and cornifin beta expression in vaginal epithelium of the rats through vitamin D3. Eur J Histochem 52:107–104Google Scholar
- 28.Zeyneloglu HB, Oktem M, Haberal NA, Esinler I, Kuscu E (2007) The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women. Fertil Steril 88(2):530–532Google Scholar
- 30.Speroff L (2003) Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 102(4):823–834Google Scholar
- 32.Ziagham Z, Abbaspoor Z, Abbaspour MR (2012) The comparison between the effects of hyaluronic acid vaginal suppository and vitamin e on the treatment of atrophic vaginitis in menopausal women. J Arak Uni Med Sci 15(6):57–64Google Scholar
- 33.Emamverdikhan AZ, Golmakani N, SharifiSistani N, Shakeri MT, Hasanzade Mofrad M, Sajadi Tabassi A (2014) Comparing two treatment methods of vitamin E suppository and conjugated estrogen vaginal cream on the quality of life in menopausal women with vaginal atrophy. J Midwif Reprod Health 2(4):253–261. https://doi.org/10.22038/JMRH.2014.3246 Google Scholar
- 34.Morali G, Polatti F, Metelitsa EN, Mascarucci P, Magnani P, Marrè GB (2006) Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy. Arzneimittelforschung 56(3):230–238Google Scholar
- 35.Dinicola S, Pasta V, Costantino D, Guaraldi C, Bizzarri M (2015) Hyaluronic acid and vitamins are effective in reducing vaginal atrophy in women receiving radiotherapy. Minerva Ginecol 67(6):523–531Google Scholar